Role of Hematopoietic Growth Factors in Radiation Victims

RhGM-CSF Following the Goiânia Accident
  • Anna Butturini
  • Robert Peter Gale

Abstract

Total-body exposure to > 1 Gy of ionizing radiation at dose rates > 1 cGy per minute suppresses hematopoiesis in humans. Severity of bone marrow inhibition, duration of decreased blood cell levels, and likelihood of spontaneous recovery are dose dependent in the range of 1–10 Gy. Although experimental and clinical data suggest that some hematopoietic stem cells survive doses of radiation ≥ 10 Gy, hematopoietic recovery is unlikely at higher doses because of toxicity to non hematopoietic organs or because supportive measures are unable to prolong survival long enough for recovery.1–3

Keywords

Bone Marrow Failure Nuclear Accident Hematopoietic Growth Factor Capillary Leak Syndrome Hematologic Recovery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    United Nations Scientific Committee on Atomic Radiation. Sources, Effects and Risks of Ionizing Radiation. 1988 Report to the General Assembly with Annexes. United Nations, NY, 1988.Google Scholar
  2. 2.
    Gale, R. P. Immediate medical consequences of nuclear accidents: Lessons from Chernobyl. JAMA 258: 625–628, 1987.PubMedCrossRefGoogle Scholar
  3. 3.
    Barabanova, A. B., Baranov, A. E., Guskova, A. K., et al. Acute Radiation Effects in Man. National Committee on Radiation Protection, Moscow, 1986.Google Scholar
  4. 4.
    Winston, D. J., Ho, W. G., Gale, R. P., et al. Therapeutic granulocyte transfusions for documented infections: A controlled trial of ninety-five infectious granulocytopenic episodes. Ann Intern Med 97: 509–515, 1982.PubMedCrossRefGoogle Scholar
  5. 5.
    Jammet, H., Mathe, G., Pendic, B., et al. Study of six cases of accidental acute total-body irradiation. Rev Fr Etud Clin Bio14: 210–225, 1959.Google Scholar
  6. 6.
    Gale, R. P., and Reisner, Y. The role of bone marrow transplants after nuclear accidents. Lancet 1: 923–925, 1988.PubMedCrossRefGoogle Scholar
  7. 7.
    Baranov, A., Gale, R. P., Guskova, A. K., et al. Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med 321: 205–212, 1989.PubMedCrossRefGoogle Scholar
  8. 8.
    Dexter, M. Growth factors: From the laboratory to the clinic. Nature 321: 198, 1986.PubMedCrossRefGoogle Scholar
  9. 9.
    Nienhuis, A. W. Hematopoietic growth factors. N Engl J Med 318: 916–918, 1988.PubMedCrossRefGoogle Scholar
  10. 10.
    Butturini, A., De Souza, P. C., Gale, R. P., et al. Use of recombinant granulocyte-macrophage colony-stimulating factor in the Brazil radiation accident. Lancet 11: 471–475, 1988.CrossRefGoogle Scholar
  11. 11.
    Brandt, S. J., Peters, W. P., Atwater, S. K., et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high dose chemotherapy and bone marrow transplantation. N Engl J Med 318: 869–876, 1988.PubMedCrossRefGoogle Scholar
  12. 12.
    Gabrilove, J. L., Jakubowski, A., Scher, H., et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414–1422, 1988.PubMedCrossRefGoogle Scholar
  13. 13.
    Vadhan-Raj, S., Keating, M., LeMaistre, A., et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545–1552, 1987.PubMedCrossRefGoogle Scholar
  14. 14.
    Bronchud, M. H., Scarffe, J. H., Thatcher, N., et al. Phase I/11 study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56: 809–813, 1987.Google Scholar
  15. 15.
    Morstyn, G., Campbell, L., Sousa, L. M., et al. Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1: 667–672, 1988.PubMedCrossRefGoogle Scholar
  16. 16.
    Champlin, R. E., Nimer, S. D., Ireland, P., et al. Treatment of refractory aplastic anemia with recombinant granulocyte-macrophage colony-stimulating factor. Blood 73: 694–699, 1989.PubMedGoogle Scholar
  17. 17.
    Steward, W. P., Scarffe, J. H., Austin, K., et al. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) given as a daily short infusion: A phase I dose-toxicity study. Br J Cancer 59: 142–145, 1989.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Anna Butturini
    • 1
  • Robert Peter Gale
    • 2
  1. 1.Department of Pediatrics, Division of Hematology and OncologyUniversity of ParmaParmaItaly
  2. 2.Department of Medicine, Division of Hematology-Oncology, School of MedicineUniversity of CaliforniaLos AngelesUSA

Personalised recommendations